To explore which genetic lesions might be associated with PRAS40 induction during mTOR inhibitor therapy, we hybridized tumor cell DNA collected during rapamycin therapy (S2) to CGH microarrays consisting of ∼40,000 oligonucleotide probes. The gene discussed is MTOR; the disease is neoplasm.